(Image from the CDC)
Becton Dickinson (NYSE:BDX) and Quidel are struggling to fulfill orders for rapid COVID-19 antigen tests as the virus continues to spread, according to a report in the Wall Street Journal.
The newspaper reported today that the two companies, which are the only ones that have FDA emergency use authorizations to sell the rapid diagnostics, cannot keep up with demand and that the Department of Defense is preparing another major order. The companies sell the analyzer equipment to perform the tests as well as the actual tests. Quidel told the Journal that it is having trouble meeting demand for analyzers, while BD is struggling to produce enough tests, the newspaper reported. Neither company immediately responded to requests for comment.
Get the full story on our sister site, Medical Design & Outsourcing.
Filed Under: Infectious Disease
